Dianthus Therapeutics, Inc. /DE/ (DNTH) 8-K Current Report: March 12, 2026
Filed: March 12, 2026
Health Care
Pharmaceutical PreparationsDianthus Therapeutics, Inc. /DE/ (DNTH) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 1.01: Entry into a Material Definitive Agreement
Dianthus Therapeutics, Inc. /DE/ 8-K Mar 12, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Offering priced at $81.00/share; 7.31M shares + 402K pre-funded warrants issued, with full 1.16M share overallotment exercised next day
- • Net proceeds ~$673.5M after underwriting discounts and offering expenses
- • Pre-funded warrants priced at $80.999 (full price minus $0.001 exercise), capped at 4.99%/9.99%/19.99% beneficial ownership limits
- • Five-bank syndicate led by Jefferies, TD Securities, Evercore, Stifel, and Guggenheim — broad institutional placement signal
- • Closing expected March 12, 2026; raises substantial cash runway for clinical-stage biotech, likely funding Phase 2/3 programs
Other Dianthus Therapeutics, Inc. /DE/ 8-K Filings
Get deeper insights on Dianthus Therapeutics, Inc. /DE/
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.